">LONDON, ONTARIO--(Marketwired - Sept. 4, 2013) - Critical Outcome Technologies Inc. (TSX VENTURE:COT) ("COTI" or the "Corporation") announced today that it has filed revised financial statements for its fiscal year ending April 30, 2013. The financial statements previously filed on SEDAR on August 27, 2013, contained clerical errors made in preparing the electronic filing that resulted in a filing that did not conform to the financial statements approved by the Board. These errors had no effect on the earnings or assets previously reported and did not affect the results reported by press release or the disclosures set out in the Company's Management Discussion and Analysis as previously filed.
About Critical Outcome Technologies Inc. (COTI)
COTI is a leading-edge technology company specializing in accelerating the discovery and development of small molecules - dramatically reducing the time and cost to bring new drugs to market. COTI's proprietary artificial intelligence system, CHEMSAS®, utilizes a series of predictive computer models to identify compounds with a high probability of being successfully developed from disease specific drug discovery through chemical optimization and preclinical testing. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.
Follow @CriticalOutcome on Twitter at http://twitter.com/CriticalOutcome.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Stocks & Offerings
- financial statements
Dr. Wayne Danter
President & CEO